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Abstract: In vitro cell-based assays have been fundamental in modern drug discovery and have led
to the identification of novel therapeutics. We have developed complex mixed central nervous system
(CNS) cultures, which recapitulate the normal process of myelination over time and allow the study
of several parameters associated with CNS damage, both during development and after injury or
disease. In particular, they have been used as a reliable screen to identify drug candidates that may
promote (re)myelination and/or neurite outgrowth. Previously, using these cultures, we demonstrated
that a panel of low sulphated heparin mimetics, with structures similar to heparan sulphates (HSs),
can reduce astrogliosis, and promote myelination and neurite outgrowth. HSs reside in either the
extracellular matrix or on the surface of cells and are thought to modulate cell signaling by both
sequestering ligands, and acting as co-factors in the formation of ligand-receptor complexes. In this
study, we have used these cultures as a screen to address the repair potential of numerous other
commercially available sulphated glycomolecules, namely heparosans, ulvans, and fucoidans. These
compounds are all known to have certain characteristics that mimic cellular glycosaminoglycans,
similar to heparin mimetics. We show that the N-sulphated heparosans promoted myelination.
However, O-sulphated heparosans did not affect myelination but promoted neurite outgrowth,
indicating the importance of structure in HS function. Moreover, neither highly sulphated ulvans
nor fucoidans had any effect on remyelination but CX-01, a low sulphated porcine intestinal heparin,
promoted remyelination in vitro. These data illustrate the use of myelinating cultures as a screen and
demonstrate the potential of heparin mimetics as CNS therapeutics.
Keywords: myelination; neurite outgrowth; cell culture; heparin sulphate; moderate
throughput screen
1. Introduction
The repair of the central nervous system (CNS) is a complex process, which requires a multifactorial
approach. Identifying molecules that promote CNS repair is an important aspect of developing
therapies for regenerative medicine. We have devised a mixed neural cell culture that can be used to
study developmental myelination, neurite outgrowth, and re/myelination after injury. The cultures
are generated from dissociated embryonic rat spinal cords and develop over time to form many
myelinated internodes separated by nodes of Ranvier [1]. They have allowed us to examine factors
that regulate the process of myelination over time and we have, therefore, termed them myelinating
cultures-development (MC-Dev). These cultures have been used to study the interaction between
oligodendrocytes and axons during the process of myelination [2] and lead to the identification of the
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novel function of chemokines as regulators of myelination. Notably, C-X-C motif chemokine 10 [3] and
connective tissue growth factor [4] can inhibit the development of myelination, while C-X-C motif
chemokine 12 can promote myelination [5,6].
We have further modified these cultures to study aspects of injury and disease. To generate an
injury, we allowed the cultures to begin to myelinate and then made a lesion using a scalpel blade.
Similar to a transection injury, we demonstrate how the neurites’ die back and the areas adjacent to
the injury become demyelinated [7]. These cultures are termed myelinating cultures-injured (MC-Inj)
and have been validated as a good model to study CNS damage using drugs known to induce repair,
including Epac and Phosphodiesterase 4 (PDE4) inhibitors [7,8]. Lastly, we used these cultures to mimic
diseases in which demyelination occurs, such as multiple sclerosis (MS). Axons were demyelinated
using complement and the myelin oligodendrocyte glycoprotein (MOG) antibody, and the resulting
cultures could be used to examine factors that promote remyelination [9,10]; we have termed these
myelinating culture-demyelination (MC-Demy) (Figure 1). These cultures can be easily generated in
large numbers, allowing us to screen several therapeutics simultaneously [1].
Previously, we demonstrated that low sulphated heparin mimetics (mHeps) could prevent features
of in vitro astrogliosis [11–13]. mHeps are glycomolecules with similar structure to heparan sulphates
(HSs), which reside either in the extracellular matrix (ECM) or on the surface of cells. mHeps have
a repeating subunit of uronic acid linked to glucosamine, present as an alternating co-polymer of
both iduronate- and glucuronate-containing sequences bearing N-sulphate, N-acetyl, and O-sulphate
substitution. They can be used to mimic the activity of HSs, which are thought to modulate cell signaling
by both sequestering ligands and acting as co-factors in the formation of ligand-receptor complexes [14].
Moreover, the biological activity of these molecules can be modified by its structure [14–17]. For this
reason, we further investigated if these mHeps could influence other neural cells and promote CNS
repair. We, therefore, applied the panel of mHeps with varying sulphation patterns to all three types of
myelinating cultures. Although the mHeps had no effect on developmental myelination (MC-Dev),
we found that low sulphated (LS) mHeps could promote myelination and neurite outgrowth and
act via sequestering inhibitors of repair in MC-Demy and MC-Inj [10]. This led us to propose that
LS-mHeps exert multiple beneficial effects on mechanisms supporting enhanced repair, and represent
novel candidates as therapeutics for CNS damage.
These promising results have now led us to screen a further library of sulphated glycomolecules,
composed of a panel of heparosans, ulvans, fucoidans, and a low sulphated heparinoid CX-01.
Heparosan is a bacterial glycosaminoglycan (GAG) obtained as a K5 capsular polysaccharide from
Escherichia coli with an analogous structure to hyaluronic acid [18]. The uronic acid epimerisation
and various sulphate groups associated with heparan sulphate/heparin are absent from the K5
polysaccharide, along with the accompanying biological function [19]. However, the K5 polysaccharide
can be enzymatically and chemically modified, producing a panel of sulphated and epimerised
derivatives, which are suitable for exploring structure-activity relationships [20].
Marine organisms have become of interest to the pharmaceutical industry as a rich source of novel
renewable therapeutic biologics, and fucoidans and ulvans are two such glycomolecules found in
seaweeds [21–23]. Fucoidans are sulphated polysaccharides extracted from brown seaweed. The exact
chemical composition varies between species, but predominantly, they are rich in galactose and
sulphated fucose chains. Numerous beneficial neurological effects have been described, including
protection from neuronal death in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Parkinson
mice [24] and reducing myelin phagocytosis through the inhibition of scavenger receptors in MS [25].
Ulvans are complex branched polysaccharides found in the cell wall of green algae, made up of
a repetitive disaccharide of 3-sulphated rhamnose and either xylose, iduronic acid, or glucuronic
acid [26,27]. Ulvans have been suggested to display antioxidant and anti-tumour effects [28,29].
Based on such characteristics, and their unique structures, ulvans have been used in numerous
biomaterials and bioscaffolds to aid repair and drug delivery [30,31]. Due to their wide-range of
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bio-activities, and their sulphated saccharide structures, fucoidans and ulvans were selected as
potentially important therapeutic glycomolecules to screen using our in vitro CNS models.
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the coverslip on day 24 (Step 4). The day after injury, cultures can be treated with therapeutics and 
the extent of neurite outgrowth (SMI31 stains axons in red, DAPI stains nuclei blue) or myelination 
(PLP stains myelin in green) adjacent to the injury site quantified (Step 5). Dotted white line 
demarcates injury site. (c) To study remyelination, the cultures are demyelinated by overnight 
incubation with the Z2 antibody that recognizes myelin oligodendrocyte glycoprotein (MOG) and 
rabbit complement at 37 °C (Step 4). The day after demyelination the cultures can be treated with 
Figure 1. Schematic of in vitro myelinating cultures MC-Dev, MC-Inj, and MC-Demy. (a) MC-Dev are
set up using astrocytes derived from neurospheres (Step 1, GFAP stains astrocytes in green) and mixed
spinal cord cells derived from embryos at day 15 (Step 2) and allowed to develop for at least 24 days
(Step 3). Therapeutics can be introduced from when the process of myelination begins (day 12–16)
to determine their effect on de novo myelination. (b) The cultures can be used to mimic CNS injury
(MC-Inj) by cutting with an 11 mm single edge razor blade pressed gently across the center of the
coverslip on day 24 (Step 4). The day after injury, cultures can be treated with therapeutics and the
extent of neurite outgrowth (SMI31 stains axons in red, DAPI stains nuclei blue) or myelination (PLP
stains myelin in green) adjacent to the injury site quantified (Step 5). Dotted white line demarcates
injury site. (c) To study remyelination, the cultures are demyelinated by overnight incubation with
the Z2 antibody that recog izes myelin oligodendrocyte glycoprotein (MOG) and rabbit complement
at 37 ◦C (Ste 4). The day after demyelination the cultures can be trea ed with therapeutics and
after 5 days the levels of remyelination quantified compared to non-treated control cultures (Step 5).
Scale bars represents 100 µm.
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The final compound in our library of glycomolecules was the low anticoagulant 2-O,
3-O desulphated heparin (ODSH, CX-01), which is a porcine intestinal heparin derivative that
retains many heparin anti-inflammatory properties. It is well-characterised, commercially available,
and is currently involved in a clinical trial for acute myeloid leukemia [32]. It was also used as an early
therapeutic intervention after traumatic brain injury and showed beneficial functional outcomes [33].
We were, therefore, interested to determine if such beneficial effects could be observed in our in vitro
CNS injury models.
Using our three complex neural cultures (MC-Inj, MC-Dev, and MC-Demy), we were able to
screen this library of sulphated polysaccharides to establish any effect on re/myelination and neurite
outgrowth. We have identified a number of interesting compounds, demonstrating the suitability of
these complex cultures for screening potential therapeutics.
2. Materials and Methods
2.1. Library of Glycomolecules
Heparosans were gifted by Glycores 2000 Srl (Milan, Italy), and ulvans were produced and
modified by Glycomar Ltd. (Oban, UK). The fucoidans were gifted for research use by Marinova Pty
Ltd. (fucoidans 1, 3 and 5, Cambridge, Australia) and FMC Biopolymer (fucoidans 2 and 4, Vormedal,
Norway). Glycomar Ltd. (UK) carried out desulphation and depolymerisation of fucoidans (fucoidans
1, 2 and 3). Cantex Pharmaceuticals (Weston, FL, USA) gifted the CX-01 compound.
2.2. Astrocytes Derived from Neurospheres
Neurospheres (NS) were generated from the striata of 1-day-old Sprague Dawley (SD) rat pups
using a method modified by [34] and differentiated into astrocytes as described in [1,3]. Neurospheres
were triturated and transferred to 13 mm poly-L-lysine (PLL; 13 µg/mL, Sigma, Gillingham, UK) coated
coverslips (Corning, Deeside, UK) and incubated for a further 5–7 days in vitro (DIV) at 37 ◦C in an
atmosphere of 7% CO2 until a confluent monolayer formed. Neurosphere-derived astrocytes were
maintained in Dulbecco’s modified Eagle’s medium (DMEM-1 g/mL glucose, Life Technologies, Paisley,
UK) with 10% fetal bovine serum (Sigma, UK) and 2 mM L-glutamine (Sigma, Gillingham, UK).
2.3. Myelinating Spinal Cord Cultures (MC-Dev)
Generation of rat myelinating cultures was based on previously described methods [1]. The spinal
cord of E15.5 Sprague Dawley (SD) embryos were enzymatically dissociated and the cell suspension
was plated at 150,000 cells per coverslip on top of the neurosphere derived astrocytes in a plating
medium (PM) that contained 50% DMEM-1 g/mL glucose, 25% horse serum (Invitrogen), 25% HBSS
(with Ca2+ and Mg2+, Life Technologies, UK), and 2 mM L-glutamine. Cells were left to adhere for 2 h
at 37 ◦C, and then supplemented with 300 µL PM and 500 µL differentiation medium, which contained
DMEM (4.5 g/mL glucose, Life Technologies, UK), 10 ng/mL biotin (Sigma, UK), 0.5% hormone mixture
(1 mg/mL apotransferrin, 20 mM putrescine, 4 µM progesterone, 6 µM selenium (formulation based
on N2 mix of [35] 50 nM hydrocortisone, and 0.5 mg/mL insulin known as DM+, or DM- if lacking
insulin (all reagents from Sigma, UK). Each dish was fed three times a week with DM+ for 12 DIV then
DM- for the following 16 DIV. To assess the effect of glycomolecules on developmental myelination,
cultures were treated at 13 DIV and 20 DIV (1 nM), following which, the cultures were fixed and
stained at 28 DIV.
2.4. Myelinating Injured Cultures (MC-Inj)
MC-Inj cultures were generated based on previously published methods [7,8]. At 24 DIV,
when myelination had begun myelinating, cultures were cut using a 11 mm single edge razor blade
(WPI, Aston, UK) pressed gently across the center of the coverslip. The cut created a focal cell free area
(650 µm) with a decrease in adjacent neurite density and myelination levels, along with a very low
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number of neurites crossing the cut area site, referred to as the lesion. Using these cultures’ myelination,
neurite density and outgrowth could be assessed using immunocytochemistry. The cultures were
treated with the panel of glycomolecules at various concentrations at 25 DIV and allowed to recover
for a further 5 DIV. Cultures were then fixed and stained as described in Section 2.6.
2.5. Demyelinated Cultures (MC-Demy)
MC-Demy cultures were generated based on our previously published methods [9,10]. At 24 DIV,
myelinating cultures were demyelinated by overnight incubation with the Z2 antibody (100 ng/mL
Hybridoma, a kind gift from Christopher Linington, University of Glasgow), which recognises
myelin oligodendrocyte glycoprotein (MOG) and a rabbit complement (100 µg/mL, Millipore, Watford,
UK) at 37 ◦C. The demyelinated cultures were then treated with the panel of glycomolecules at
various concentrations, following which, cultures were fixed and stained at 30 DIV. Additionally,
a conditioned medium was collected at 28 DIV for CytoTox 96® Non-Radioactive Cytotoxicity Assay
(Promega G1780, Southampton, UK) to assess the viability of cultures under treatment following
manufacturers guidelines.
2.6. Immunocytochemistry
Myelinating cultures were fixed with 4% paraformaldehyde (4% PFA, Sigma, UK) for 20 min at
room temperature (RT) and permeabilised with 0.2% Triton X-100 (Sigma, UK) at RT for 15 min, once the
washed cultures had been blocked with phosphate-buffered saline (PBS) with 0.2% porcine gelatin
(blocking buffer, Sigma, UK) for 1 h at RT. The primary antibodies were diluted in a blocking buffer,
and the cells were incubated for 1 h at RT. Mature myelin (proteolipid protein, PLP) was visualised
using the AA3 antibody (1:100, anti-rat; hybridoma supernatant [36]), and a neurofilament was detected
using SMI31 (mouse IgG1, 1:1500, BioLegend, London, UK). After washing, the cultures were incubated
with the appropriate secondary antibodies for 45 min at RT, and mounted in a Vectashield (Vector
Laboratories, Peterborough, UK).
2.7. Microscopy and Image Analysis
For all myelinating cultures, the coverslips were imaged using Olympus BX51 (Olympus, Essex,
UK) or LAS AF Leica DM4000 B fluorescence microscopes (Leica Microsystems, Milton Keynes,
UK), with the experimenter blinded to the conditions [6]. For quantitative analysis of MC-Inj,
the region adjacent to the lesion edge running 0–670 µm across the length of the coverslip was imaged
at 20× magnification to allow quantification of neurite density and myelination at the end of the
experiment. For quantification of neurite outgrowth, the entire length of the injury site was imaged,
with the exception of areas that were folded due to the mechanical effect of cutting, which were
not imaged [7]. For MC-Dev and MC-Demy quantification of re/myelination and neurite density,
images were taken at 10× magnification (as seen from example images in Figure 1). For each coverslip,
10 images were taken randomly, covering the entire coverslip. In each biological repeat, coverslips
were stained in triplicate; thus, 30 images were taken per condition (at least n = 3 biological repeats).
The analysis of treated cultures was carried out by a comparison to non-treated control cultures run in
parallel. (non-treated injured cultures and non-treated demyelinated cultures for MC-Inj and Demy,
respectively).
2.8. Re/myelination Quantification
For all myelinating cultures, the coverslips were stained using antibodies SMI31 and AA3 for
neurites and myelin, respectively. Quantification of re/myelination was carried out using CellProfiler
Image Analysis software (Broad Institute) and is available to download at https://github.com/muecs/
cp [37,38]. CellProfiler uses pattern recognition software to distinguish between linear myelinated
internodes and oligodendrocyte cell bodies. In this manner, we track the co-expression of myelin sheaths
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(PLP) and axons (SMI31), which ignores oligodendrocytes that do not contact axons, and therefore
allows us to calculate the percentage of myelinated fibers.
2.9. Neurite Outgrowth
Neurite outgrowth was defined as an SMI31 positive projection, which enters and crosses the lesion
site. The number of neurites that crossed the lesion site was counted for each image. Any uninjured
area around the lesion was excluded from analysis. Regions of neuronal bundles typically extended
from one dense region and were, therefore, quantified as one projection, if individual neurites could
not be detected. The number of neurites per image was averaged across the lesion and termed neurite
outgrowth per field of view.
2.10. Statistical Analysis
Data are presented as the mean + SEM and were analysed using ANOVA with a Dunnett post-test
for multiple comparisons using Prism software version 6.0 (GraphPad Software, San Diego, CA,
USA). Differences were considered significant at p < 0.05. Each experimental n was the average of
3 technical replicates.
3. Results
3.1. Heparosans K5 NS and (Epi) K5 OS (H) Promote CNS Repair in MC-Inj
Tables detailing the panel of heparosans used in this investigation are shown in Figure 2a. MC-Inj
cultures were treated with a titration of each heparosan (1, 10, and 100 ng/mL) followed by an
assessment of myelination and neurite outgrowth (summarised in Figure 2a). K5 NS at 1 ng/mL,
10 ng/mL, and 100 ng/mL was the only heparosan found to significantly promote myelination (~3 fold)
compared to the non-treated control cultures (p = 0.0015, p = 0.015 and p = 0.0003, respectively;
Figure 2b,c). However, its epimerised form did not have a similar pro-myelinating effect, suggesting
that the conformation of the uronic acid residue is important for function. Interestingly, neither forms
of this heparosans had any effect on neurite outgrowth. Conversely, O-sulphated heparosan Epi K5 OS
(H) promoted neurite outgrowth compared to the non-treated control cultures (Figure 2d,e). Epi K5
OS (H) treatments at 1 ng/mL, 10 ng/mL, and 100 ng/mL resulted in a significantly increased neurite
outgrowth of 51%, 43%, and 67%, respectively (p = 0.0048, p = 0.030 and p = 0.0001, respectively).
These data imply that epimerisation is also a vital heparosan modification for the observed effect on
neurite outgrowth.
3.2. Heparosans Do Not Affect the Development of Myelination in MC-Dev or Remyelination in MC-Demy
The same panel of heparosans (detailed in Figure 2a) was used to treat MC-Dev and were found
to have no effect on developmental myelination or on neurite density, similar to results previously
published by us using sulphated polysaccharides [10] (Figure 3a,b). This suggests that the beneficial
effect on myelination following K5 NS treatment in the MC-Inj screen is unlikely to be a direct effect
on the compounds ability to promote oligodendrocyte precursor cell (OPC) differentiation and/or the
process of oligodendrocyte ensheathment of axons. To determine whether pro-myelinating effects
could be observed in a different injury model, we tested the panel of heparosans using MC-Demy
(Figure 3c,d). Cultures were treated with each compound at 1 nM to enable a direct comparison
between compounds. However, at this concentration, there were no significant improvements in
remyelination observed for any of the panel, with only a small trend towards an increase after Epi K5
NS and Epi K5 NOS (H) treatment (Figure 3c,d). A dose response for Epi K5 NS was carried out and
demonstrated no significant effect on remyelination [39].
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Figure 2. Heparosan screen using MC-Inj. (a) Table of the panel of heparosans used to treat
MC-Inj detailing the predominant disaccharide, the % sulphate by MW (based on modified Terho
method) and concentrations at which any significant increases were detected for each parameter
tested. (b) Representative images of MC-Inj at 30 DIV showing areas adjacent to the lesion in control
and after treatment with K5 NS at 100 ng/mL (SMI31 stains neurites in red, PLP stains myelin in
green). (c) Quantification of K5 NS treatment shows that it significantly promotes myelination adjacent
to the lesion at 1 ng/mL, 10 ng/mL, and 100 ng/mL compared to the non-treated injured control
cultures (one-way ANOVA with Dunnett multiple comparison, ** p = 0.0015, * p = 0.015 *** p = 0.0003,
respectively). (d) Representative images of MC-Inj lesion at 30 DIV showing the non-treated control
and following treatment with Epi K5 OS at 100 ng/mL (SMI31 stains neurites in red). Injury site
demarcated with white dotted lines. (e) Quantification of Epi K5 OS (H) treatment at 1 ng/mL,
10 ng/mL and 100 ng/mL showed significant increases in neurite outgrowth compared to the non-treated
injured control cultures at all concentrations (one-way ANOVA with Dunnett multiple comparison,
** p = 0.0048, * p = 0.030 and *** p = 0.0001, respectively); ns, non-significant, Scale bars represent 50 µm
in all images, error bars + SEM (all heparosan treatments n = 3; technical replicates n = 3).
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3.3. Fucoidans or Ulvans Did Not Affect the Level of Remyelination in MC-Demy
Details of the panel of fucoidans and ulvans screened in MC-Demy are shown in Figure 4a,b.
Fucoidans (Figure 4c,d) and ulvans (Figure 4e,f) were used to treat MC-Demy at 1 nM and 1 µM
concentrations. None of the fucoidans or ulvans at either concentration had any effect on remyelination
or neurite density. A toxicity screen was also carried out for each fucoidan and ulvan via collection
of the growth medium from the cultures after treatment. This conditioned medium was assessed
for cellular toxicity using a cytotox non-radioactive assay. It was found that treatments at the higher
concentration of 1 µM for fucoidans 1, 4, and 5 (Fuc1, Fuc4, Fuc5) were toxic to cultures as indicated
in the 28 DIV toxicity screen (Figure 4g). Conversely, none of the ulvans had any toxic effects even
at 1 µM.
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used to treat MC-Demy. (c) MC-Demy were treated with fucoidans at either 1 nM or 1 µM on 25 DIV
and allowed to recover until 30 DIV, when they were immunolabelled with SMI31 and PLP. There was
no significant effect on the level of remyelination after fucoidan treatment at either concentration tested.
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Fucoidan 1, 4 and 5 treatments at 1 µM were toxic and killed the cultures by 30 DIV, meaning that
myelination and neurite density could not be quantified. (d) All fucoidans tested had no effect on
neurite density at either concentration tested. (e) Quantification of remyelination following treatment
with ulvans at either 1 nM or 1 µM suggests that none of these compounds had any effect compared
to non-treated control cultures (Demy 5). (f) Quantification of neurite density showed no difference
after treatment. (g) Conditioned media from the cultures were collected at 28 DIV, 2 days prior to
immunolabelling and used to assess cytotoxicity based on LDH levels. The toxicity of Fucoidan 1,
4 and 5 was indicated in the early cytotoxicity assay with Fuc 4 already showing significant toxicity
prior to culture death (one-way ANOVA with Dunnett multiple comparison, * p = 0.0366). Error bars +
SEM (n = 4; technical replicates = 3).
3.4. CX-01 Promotes Remyelination in MC-Demy
We also assessed the effect of CX-01 in MC-Demy using a titration ranging from 1 ng/mL to
1000 ng/mL. Treatment with CX-01 resulted in a significant increase in remyelination compared to
the non-treated demyelinated control cultures (Demy5) at 50 ng/mL and 250 ng/mL (Figure 5a,b,
p = 0.02). CX-01 had no effect on neurite density (Figure 5c). We also assessed if CX-01 was cytotoxic,
by testing the growth medium after drug treatment. CX-01 was found not to be cytotoxic to the cultures
supporting its potential use in treating neural cells (Figure 5d).
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Representative i ages of control cultures or those treated ith anti- and co ple ent on either
Biology 2019, 8, 52 11 of 15
25 DIV (Demy 0), or 30 DIV (Demy 5) and following CX-01 treatment at 50 ng/mL and 250 ng/mL.
(b) Quantification showing treatment with CX-01 resulted in an average 75% increase in remyelination
compared to the non-treated demyelinated control cultures on day 5 (Demy 5) at 50 ng/mL and 250 ng/mL
(one-way ANOVA with Dunnett multiple comparison, * p = 0.0238 and 0.0222). (c) Quantification of
neurite density showed no effect. (d) Conditioned media from the cultures were collected at 28 DIV,
2 days prior to immunolabelling, and used to assess cytotoxicity based on LDH levels. Quantification
of cytotoxicity showed no change after treatment implying no adverse toxic effects on the cultures.
Scale bars represent 100 µm in all images, error bars + SEM (n = 6; technical replicates = 3).
4. Discussion
In this study, we have used several modifications of myelinating cultures to screen a range
of glycomolecules that mimic the HS found around the ECM and cell surface. HS are known to
modulate the biological activity of a diverse range of molecules including chemokines, growth factors,
morphogens, and adhesion molecules leading to a regulatory role in many physiological and
pathological conditions [17]. They have also been used as pharmacological agents to treat a
range of diseases [40,41]. The application of therapeutics for cancer treatment has been reported
for non-coagulant heparin (SST001) and a phosphomannopentaose sulphate (PI-88) that targets
heparanase [40,41]. PI-88 is in clinical trial for the treatment of liver cancer, non-small cell lung cancer,
melanoma, and prostate cancer (ClinicalTrials.gov). Similarly, CX-01 is currently in clinical trials for
myeloid leukaemia and cervical cancer [42]. Thus, it is clear that these HS mimetics have the potential
to treat human disease and have been shown to produce very few side effects. However, there is no
evidence from clinical trials that these molecules can be used to aid repair following CNS disease/injury.
Previously, we demonstrated using a panel of mHeps that the level of sulphation
effected their potential to promote re/myelination and neurite outgrowth as well as decreasing
characteristics of astrogliosis with only low sulphated mHeps promoting repair [11–13]. Moreover,
their mechanism-of-action appeared to function via sequestering molecules that inhibited the repair
process [10]. This was substantiated by other studies, which demonstrated that heparin promotes PNS
myelination in DRG via the specific inhibition of the soluble immunoglobulin (Ig)-containing isoforms
of neuregulin 1 (i.e., NRG1 types I and II), which negatively regulate myelination [43].
These data were encouraging and lead us to consider whether other similar sulphated
glycomolecules would be useful for CNS repair. However, to test these reagents in animal models
is both time consuming and requires a large number of animals. For this reason, we screened the
panel of glycomolecules using our three modified myelinating cultures. It was found that only
CX-01 and K5 NS demonstrated comparable pro-myelinating results, as seen previously for the low
sulphated mHeps [10]. This suggests that N-sulphation is an important facet for promoting CNS
myelination following injury. This is supported by a recent structure relationship activity study,
which highlighted the importance of N-sulphation in facilitating specific protein interactions [16].
Conversely, the number of neurites crossing the lesion was only increased following treatment with
highly sulphated epimerized Epi K5 OS (H), implying that O–sulphation might be a desirable feature
for eliciting beneficial neurite outgrowth effects. The presence of O-sulphate moieties was deemed
essential to the activity of K5 derivatives as FGF signalling inhibitors [44]. Furthermore, modulation
of 6-O-sulphation has been shown to be imperative to Wnt signaling, which is known to regulate
numerous aspects of neural precursor development [45–48]. Our data suggests that the epimerization
state of the uronic acid may be a key structural feature for effecting myelination and neurite outgrowth.
Thus, the epimerisation of glucuronic acid to its C5 epimer could be important for protein binding.
The iduronic acid residue has additional conformational flexibility due to its ability to reside in the skew
boat conformation; the subsequent kinking of the backbone could improve protein binding [49,50].
Interestingly, neither ulvans nor fucoidans had any effect on remyelination; these glycomolecules are
composed of fucose/galactose and rhamnose/xylose/uronic acid respectively. This suggests that the
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glucosamine–uronic acid repeating sugar backbone present in K5 NS and CX-01 is imperative to the
HS function in regulating CNS cell biology. The molecular weight and the concomitant degree of
polymerisation is also a key feature for GAG activity—for example, the depolymerisation of fucosylated
glycosaminoglycan reduced anticoagulant activity in vitro [51]. Hence, we assessed both the high and
low molecular weight derivatives of fucoidans and ulvans using our cultures, but this had no effect on
the lack of activity following treatment.
Using these modified myelinating cultures allowed us to pre-screen panels of glycomolecules,
and to assess parameters, including myelination, remyelination, neurite density, and neurite outgrowth,
before validation in vivo. Moreover, molecular techniques, such as PCR and Western Blotting, can be
used to quantify data and examine the mechanism of action of treatment [7,8,10] or direct visualisation
using time lapse [2]. Since these cultures contain many neural cells types, we can also make indirect
observations by comparing drug treatment on the monocultures of OPCs, astrocytes, and microglia
with the myelinating cultures. This, in turn, allows the investigation of cross-talk between the
neural/immune cells present in the complex cultures, as previously discussed [52]. These cultures can,
therefore, mimic aspects of the cellular interactions that occur in vivo.
5. Conclusions
In summary, the present study has demonstrated the efficacy of complex myelinating cultures
modified to examine features of CNS repair to gain important information on a large panel of
glycomolecules. Thus, we propose using such cultures as a useful, moderate screen to be used before
testing potential therapeutic effects in animal models.
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